TAI · 6472.TW
Bora Pharmaceuticals Co., Ltd.
NT$379.00-NT$13.00 (-3.32%)
Bora Pharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 41.78% below the high.
Loading market information…
TWO · 4114.TWO · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Synmosa Biopharma Corporation’s quoted price sits in the lower half of its reported 52-week range, 8.54% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Synmosa Biopharma Corporation’s forward annual dividend is NT$0.85 per share, paid annual. The forward yield is 2.95% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Synmosa Biopharma Corporation’s next earnings report is currently expected on Nov 18, 2026, with estimated earnings per share of NT$0.41. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Synmosa Biopharma Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Synmosa Biopharma Corporation, established in Taipei, Taiwan, in 1980, operates as a dedicated specialty pharmaceutical enterprise. The company manages the entire lifecycle of pharmaceutical and healthcare products, from research and development to manufacturing, marketing, and distribution, primarily serving the Taiwanese market under its proprietary Synmosa brand. Its diverse product portfolio addresses key therapeutic categories, including cardiovascular health, respiratory conditions, urology, sex hormone treatments, and oncology. These offerings are available in various formats such as effervescent tablets, granules, nasal sprays, metered-dose inhalers, hormonal preparations, and other specialized forms. Beyond its proprietary products, Synmosa also extends its expertise through contract manufacturing services. The company maintains a significant international presence, exporting its goods to numerous countries including South Africa, China, Hong Kong, Thailand, Singapore, Malaysia, Vietnam, Myanmar, Cambodia, Peru, Costa Rica, and Nicaragua.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:34 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 | May 13, 2025 | NT$0.44 | NT$1.45B |
|---|
| Q4 2024 | Mar 6, 2025 | NT$0.32-32.94% vs estimate | NT$1.51B+4.25% vs estimate |
|---|
| Q3 2024 | Nov 14, 2024 | NT$0.39-24.86% vs estimate | NT$1.42B+1.69% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$379.00-NT$13.00 (-3.32%)
Bora Pharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 41.78% below the high.
NT$167.50-NT$5.00 (-2.9%)
Lotus Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 54.67% below the high.
NT$28.55-NT$0.80 (-2.73%)
Center Laboratories, Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.69% below the high.
NT$79.90-NT$0.50 (-0.62%)
TTY Biopharm Company Limited’s quoted price sits in the upper half of its reported 52-week range, 8.16% below the high.
NT$59.70-NT$0.10 (-0.17%)
YungShin Global Holding Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.71% below the high.
NT$56.70-NT$0.20 (-0.35%)
Standard Chem & Pharm Co. Ltd.’s quoted price sits in the upper half of its reported 52-week range, 6.36% below the high.
NT$23.30-NT$0.20 (-0.85%)
Orient Pharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 21.28% below the high.
NT$50.00-NT$1.80 (-3.47%)
Panion & Bf Biotech Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.55% below the high.
